The incidences of thromboembolic events, hepatotoxicity, cataracts, prolonged QT interval, and myelofibrosis in patients treated with other approved TPO-RAs are worth mentioning, with such drugs including romiplostim, eltrombopag and avatrombopag [10, 15, 18]. This evidence concerns the gene TPO and myelofibrosis.